{"organizations": [], "uuid": "df084748df99508c99ae38c6fe732600bac309b0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/09/globe-newswire-bio-path-holdings-to-announce-first-quarter-2018-financial-results-on-may-16-2018.html", "country": "US", "domain_rank": 767, "title": "Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-05-09T16:00:00.000+03:00", "replies_count": 0, "uuid": "df084748df99508c99ae38c6fe732600bac309b0"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/09/globe-newswire-bio-path-holdings-to-announce-first-quarter-2018-financial-results-on-may-16-2018.html", "ord_in_thread": 0, "title": "Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018", "locations": [], "entities": {"persons": [{"name": "bio-path", "sentiment": "none"}], "locations": [{"name": "houston", "sentiment": "none"}, {"name": "bio-path", "sentiment": "none"}], "organizations": [{"name": "bio-path holdings", "sentiment": "negative"}, {"name": "bio-path holdings, inc.", "sentiment": "neutral"}, {"name": "bio-path holdings, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "HOUSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 16, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018 and to provide a business overview.\nTo access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 1096178. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com . An archived webcast will be available on the Bio-Path website approximately two hours after the event.\nAbout Bio-Path Holdings, Inc.\nBio-Path is a biotechnology company developing DNAbilize ® , a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.\nFor more information, please visit the Company's website at http://www.biopathholdings.com .\nContact Information:\nInvestors\nWill O’Connor\nStern Investor Relations\n212-362-1200\nwill@sternir.com\nDoug Morris\nInvestor Relations\nBio-Path Holdings, Inc.\n832-742-1369\nSource:Bio-Path Holdings, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=OkEzio9-SIuCIR51AKS72S6xELwE-f_2CaGjMgHKxDaPl4q1LP9E7lLw4U7b-1gVnROsefN869N8EZpSv4k7FKHt1BeQpTz-QyrS-MW2s60=", "https://www.globenewswire.com/Tracker?data=CJH2Aog1quK78bJ0SNwYPRHtAqyamluNul0-P1RQzHL8ogUP1461q18i__ocWQtnyjtvqU1SRqG_rjT04jukb1vNd2dJuI8xRnqLPy4BlQpyOz-cgDxp3GgSMzvzOUBf", "https://www.globenewswire.com/Tracker?data=f3yjTHUqaxS-NsRLva_xHa7rpaO6zCMAFOn6tA6t_V-vuy_RDVS_uvZrKZm4MIKVFlJhk7zed2Xne_CJnAJpZg=="], "published": "2018-05-09T16:00:00.000+03:00", "crawled": "2018-05-09T16:22:25.004+03:00", "highlightTitle": ""}